1. Home
  2. TBPH vs LAES Comparison

TBPH vs LAES Comparison

Compare TBPH & LAES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • LAES
  • Stock Information
  • Founded
  • TBPH 2013
  • LAES 2022
  • Country
  • TBPH United States
  • LAES Switzerland
  • Employees
  • TBPH N/A
  • LAES N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • LAES Semiconductors
  • Sector
  • TBPH Health Care
  • LAES Technology
  • Exchange
  • TBPH Nasdaq
  • LAES Nasdaq
  • Market Cap
  • TBPH 536.5M
  • LAES 453.6M
  • IPO Year
  • TBPH N/A
  • LAES N/A
  • Fundamental
  • Price
  • TBPH $10.90
  • LAES $2.98
  • Analyst Decision
  • TBPH Strong Buy
  • LAES Strong Buy
  • Analyst Count
  • TBPH 5
  • LAES 1
  • Target Price
  • TBPH $16.60
  • LAES $6.00
  • AVG Volume (30 Days)
  • TBPH 158.6K
  • LAES 10.3M
  • Earning Date
  • TBPH 08-12-2025
  • LAES 09-24-2025
  • Dividend Yield
  • TBPH N/A
  • LAES N/A
  • EPS Growth
  • TBPH N/A
  • LAES N/A
  • EPS
  • TBPH N/A
  • LAES N/A
  • Revenue
  • TBPH $65,266,000.00
  • LAES $10,981,000.00
  • Revenue This Year
  • TBPH $51.74
  • LAES N/A
  • Revenue Next Year
  • TBPH N/A
  • LAES N/A
  • P/E Ratio
  • TBPH N/A
  • LAES N/A
  • Revenue Growth
  • TBPH 6.11
  • LAES N/A
  • 52 Week Low
  • TBPH $7.44
  • LAES $0.29
  • 52 Week High
  • TBPH $11.88
  • LAES $11.00
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 45.21
  • LAES 36.13
  • Support Level
  • TBPH $10.90
  • LAES $3.06
  • Resistance Level
  • TBPH $11.26
  • LAES $3.30
  • Average True Range (ATR)
  • TBPH 0.24
  • LAES 0.23
  • MACD
  • TBPH -0.08
  • LAES -0.06
  • Stochastic Oscillator
  • TBPH 2.00
  • LAES 5.77

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.

Share on Social Networks: